Kineta Adds to Its Pipeline of Venom-Derived Drug Candidates, In-licenses
Conotoxin Program for Non-Narcotic Pain Relief
Cone snail derivative one of two Kineta drug programs featured in current
National Geographic magazine story on healing power of venom-derived compounds
SEATTLE -- January 24, 2013
Kineta is pleased to announce it has secured exclusive, worldwide development
rights from the University of Utah Research Foundation to a portfolio of drug
candidates based on the Conotoxin Rg1a for the non-narcotic treatment of
chronic pain. Derived from the Rg1a peptide found in the venom of cone snails,
these molecules were discovered in the pioneering laboratory of Baldomero
Olivera, Ph.D. and are featured in an article in the February issue of
National Geographic magazine.
“This is a tremendous opportunity for Kineta to leverage its expertise in
venom peptide therapeutics to provide a medical solution to an emergent need.
We have in our hands the potential to replace some of the most dangerous and
abused prescription drugs on the market - opioid analgesics including morphine
and oxycontin. It is imperative that our industry develop treatments for
chronic pain that are potent and effective without producing the destructive,
sometimes deadly side-effects of opioid drugs,” said Shawn P. Iadonato, Ph.D.,
Kineta’s Chief Scientific Officer and Executive Vice President. Dr. Olivera
has an established record of discovering successful conotoxin-derived
molecules; the FDA approved non-narcotic pain medicine Prialt® (Zicoconotide)
is based on his laboratory’s seminal work.
Cone snails are “like little drug companies that have engineered their own
compounds to suit their needs,” Dr. Olivera explains to readers in the
National Geographic story, “A Healing Bite”. Peptides like those in cone snail
venom block excitatory ion channels in the neurons that transmit pain signals
to the brain without affecting the brain itself, and thus do not produce
tolerance or addiction or affect mental acuity.
The National Geographic story is a scientific overview of the therapeutic
potential of venom that also features a second Kineta drug candidate, ShK-186.
Derived from a venom peptide of the Caribbean Sea anemone, ShK-186 is Kineta’s
lead clinical stage autoimmune drug candidate. The National Geographic article
highlights its ability to suppress self-reactive inflammatory processes in
autoimmune diseases such as multiple sclerosis and lupus without shutting down
the entire immune system. ShK-186 was originally developed in the lab of K.
George Chandy, M.D., Ph.D. at the University of California, Irvine who is
quoted in the article as saying “… anecdotal reports from patients in the
field have been inspiring to my team, and encourage us to fully explore venom
as a wellspring of potential new therapies.” Kineta obtained development
rights and has advanced ShK-186 into Phase 1 human clinical trials.
All of Kineta’s venom-derived medicines are made synthetically without harming
or harvesting marine animals. The company strongly supports National
Geographic magazine’s concluding thesis that drug development is another vital
reason for conserving biodiversity. For more information on today’s
announcement or to schedule interviews, contact Meg O’Conor, Investor
Relations Director, email@example.com, 206-251-8638.
Prialt® is a registered trademark of Jazz Pharmaceuticals International
Kineta, Inc. is a Seattle-based privately held biotechnology company
specializing in clinical advancement of novel drug candidates derived from
leading edge scientific research. Our world class scientists are pioneers in
developing life-changing classes of new drugs designed to be more effective
and safer than current medicines. Kineta seeks to improve the lives of
millions of people suffering from autoimmune and viral diseases and from
severe pain. Our progressive business model focuses on targeting unmet medical
needs and rapid achievement of important clinical milestones. For more
information on Kineta, Inc. visit our website, www.Kinetabio.com
NOTICE: This document contains certain forward-looking statements, including
without limitation statements regarding Kineta’s plans for clinical studies.
You are cautioned that such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties inherent in Kineta’s
business which could significantly affect expected results, including without
limitation progress of drug development, clinical testing and regulatory
approval, developments in raw material and personnel costs, and legislative,
fiscal, and other regulatory measures. All forward-looking statements are
qualified in their entirety by this cautionary statement, and Kineta
undertakes no obligation to revise or update any forward-looking statement to
reflect events or circumstances after the issuance of this press release.
Meg O’Conor, 206-251-8638
Investor Relations Director
Press spacebar to pause and continue. Press esc to stop.